Please login to the form below

Not currently logged in
Email:
Password:

InterMune names Jonathan Leff executive VP of R&D

Former chief medical officer at KaloBios has experience at Merck, Amgen and Roche

InterMune has appointed Jonathan Leff to the newly created position of executive VP of R&D, effective from February 27, 2012.

Leff joins the US biotech from KaloBios Pharmaceuticals, where he was vice president and chief medical officer.

In his new role, Leff will be responsible for leading and overseeing all groups within the company's R&D organisation.

He will also provide regulatory and medical support for the commercialisation of the company's products and help expand InterMune's product portfolio.

Dan Welsch, chairman, CEO and president of InterMune, said: “As we begin to execute our plans to achieve InterMune's Vision 2015 Strategic Plan, now is the appropriate time to bring additional talent to our senior leadership team to better co-ordinate and lead the growing size, scale and complexity of our scientific endeavours”.

Prior to joining his position at KaloBios, Leff served as chief medical officer at Halozyme Therapeutics, and was previously vice president and global head of inflammation clinical development at Roche.

Other earlier roles include vice president of North America medical affairs at Amgen and senior director at Merck.

13th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics